berotek has been researched along with Metabolic Diseases in 1 studies
Fenoterol: A synthetic adrenergic beta-2 agonist that is used as a bronchodilator and tocolytic.
fenoterol : A member of the class resorcinols that is 5-(1-hydroxyethyl)benzene-1,3-diol in which one of the methyl hydrogens is replaced by a 1-(4-hydroxyphenyl)propan-2-amino group. A beta2-adrenergic agonist, it is used (as the hydrobromide salt) as a bronchodilator in the management of reversible airway obstruction.
Metabolic Diseases: Generic term for diseases caused by an abnormal metabolic process. It can be congenital due to inherited enzyme abnormality (METABOLISM, INBORN ERRORS) or acquired due to disease of an endocrine organ or failure of a metabolically important organ such as the liver. (Stedman, 26th ed)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tzvetkov, MV | 1 |
| Matthaei, J | 1 |
| Pojar, S | 1 |
| Faltraco, F | 1 |
| Vogler, S | 1 |
| Prukop, T | 1 |
| Seitz, T | 1 |
| Brockmöller, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effects of Genetic Polymorphisms in the Organic Cation Transporter OCT1 on Cellular Uptake and Metabolism of Antidepressants and Other Organic Cationic Drugs[NCT02054299] | Phase 1 | 48 participants (Actual) | Interventional | 2013-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for berotek and Metabolic Diseases
| Article | Year |
|---|---|
Increased Systemic Exposure and Stronger Cardiovascular and Metabolic Adverse Reactions to Fenoterol in Individuals with Heritable OCT1 Deficiency.
Topics: Alleles; Biological Transport; Blood Glucose; Cardiovascular System; Drug-Related Side Effects and A | 2018 |